Skip to main content
. 2021 Sep 28;12:704836. doi: 10.3389/fimmu.2021.704836

Figure 4.

Figure 4

PA protected organoids H/R injury via an IL-33/ST2 signal. (A) The relative mRNA and protein level of IL-33 in the organoid from WT-Organoids + ILC2. (B) HE staining, ZO-1, Occludin and Ki67 immunofluorescent staining in the organoid from WT-Organoids + ILC2, scale bar is 20 μm (n = 6). (C, D) Relative organoids viability and LDH levels were detected in a co-culture system of organoids and ILC2 after H/R (n = 6). (E, F) The relative fluorescence intensity quantification analysis of ZO-1, Occludin and Ki67 in the organoids (n = 6). (G) Relative mRNA level of Lgr5 in the organoids was measured by quantitative PCR (n = 6). (H) The relative protein level of IL-13 in the organoid supernatant determined by ELISA (n = 6). The results are expressed as the mean ± SEM (A, C–H). *p < 0.05, **p < 0.01, ***p < 0.001, NS means No statistically significant difference by one-way ANOVA (Tukey’s test). PA, pravastatin; H/R, hypoxia/reoxygenation; ILC2, type II innate lymphoid cells; LDH, lactate dehydrogenase; WT-Organoids + ILC2, co-cultured WT-organoids and WT-ILC2; IL-33-/–Organoids + ILC2, co-cultured IL-33-/- organoids and WT-ILC2.